Why the study?
The effectiveness of SGLT2i therapy on total (first and subsequent) CVD among patients with T2D in clinical practice remains uncertain.
Does SGLT2i therapy reduce total cardiovascular events compared to DPP4i therapy in adult patients with type 2 diabetes?
Population
8384 adult patients with T2D (1632 propensity score-matched pairs)
Comparison
SGLT2i vs DPP4i therapy
Design
Retrospective cohort study
Follow-up
Up to 6 years
Authors
Loading...
May support SGLT2i preference in high-risk diabetes; leaves open causal confirmation by randomized trials.
Does SGLT2i therapy reduce total cardiovascular events compared to DPP4i therapy in adult patients with type 2 diabetes?
In real-world clinical practice, SGLT2 inhibitors are associated with a reduced burden of total cardiovascular events compared to DPP4 inhibitors in patients with type 2 diabetes, particularly among those at high cardiovascular risk.
Su et al. (2024) studied this question.